AU2019342755B2 - Methods of reversing ticagrelor activity - Google Patents

Methods of reversing ticagrelor activity

Info

Publication number
AU2019342755B2
AU2019342755B2 AU2019342755A AU2019342755A AU2019342755B2 AU 2019342755 B2 AU2019342755 B2 AU 2019342755B2 AU 2019342755 A AU2019342755 A AU 2019342755A AU 2019342755 A AU2019342755 A AU 2019342755A AU 2019342755 B2 AU2019342755 B2 AU 2019342755B2
Authority
AU
Australia
Prior art keywords
ticagrelor
seq
hours
fab
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019342755A
Other languages
English (en)
Other versions
AU2019342755A1 (en
Inventor
David James Ballance
John Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sfj Pharma X Inc
Original Assignee
Sfj Pharma X Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69887913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019342755(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sfj Pharma X Inc filed Critical Sfj Pharma X Inc
Publication of AU2019342755A1 publication Critical patent/AU2019342755A1/en
Assigned to SFJ PHARMACEUTICALS X, LTD. reassignment SFJ PHARMACEUTICALS X, LTD. Request for Assignment Assignors: PHASEBIO PHARMACEUTICALS, INC.
Assigned to SFJ Pharma X, Inc. reassignment SFJ Pharma X, Inc. Amend patent request/document other than specification (104) Assignors: SFJ PHARMACEUTICALS X, LTD.
Application granted granted Critical
Publication of AU2019342755B2 publication Critical patent/AU2019342755B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019342755A 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity Active AU2019342755B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862733892P 2018-09-20 2018-09-20
US62/733,892 2018-09-20
US201962806225P 2019-02-15 2019-02-15
US62/806,225 2019-02-15
US201962836373P 2019-04-19 2019-04-19
US62/836,373 2019-04-19
PCT/US2019/052173 WO2020061465A1 (en) 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity

Publications (2)

Publication Number Publication Date
AU2019342755A1 AU2019342755A1 (en) 2021-05-06
AU2019342755B2 true AU2019342755B2 (en) 2025-12-11

Family

ID=69887913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019342755A Active AU2019342755B2 (en) 2018-09-20 2019-09-20 Methods of reversing ticagrelor activity

Country Status (13)

Country Link
US (1) US20210347915A1 (https=)
EP (2) EP4653465A3 (https=)
JP (2) JP7478975B2 (https=)
KR (2) KR20250161038A (https=)
CN (1) CN113194821B (https=)
AU (1) AU2019342755B2 (https=)
CA (1) CA3113654A1 (https=)
DK (1) DK3852617T3 (https=)
ES (1) ES3042247T3 (https=)
FI (1) FI3852617T3 (https=)
MX (1) MX2021003298A (https=)
PL (1) PL3852617T3 (https=)
WO (1) WO2020061465A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru
EP4337253A4 (en) * 2021-05-10 2025-03-19 Sfj Pharmaceuticals X, Ltd. Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
KR102952285B1 (ko) 2021-07-13 2026-04-13 주식회사 엘지에너지솔루션 전지의 용접 상태 검사 방법
US20260022197A1 (en) * 2024-07-16 2026-01-22 SFJ Pharma X, Inc. Methods of reversing ticagrelor activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160130366A1 (en) * 2014-10-01 2016-05-12 Medimmune Limited Antibodies to ticagrelor and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03154867A (ja) * 1989-11-13 1991-07-02 Teijin Ltd １―メチルアデノシンの免疫学的測定方法，そのための測定試薬及び試薬キット
MX2013014035A (es) * 2011-06-01 2014-01-23 Astrazeneca Ab Nuevo co-cristal ticagrelor.
AU2013344796B2 (en) * 2012-11-16 2016-11-10 Novartis Ag Use of IL-1 beta binding antibodies for treating peripheral arterial disease
KR20220041957A (ko) * 2013-03-15 2022-04-01 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
WO2016033424A1 (en) * 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
JP2018502894A (ja) * 2015-01-27 2018-02-01 アストラゼネカ アクチボラグ 心筋梗塞の病歴がある患者においてアテローム血栓性イベントを治療または予防する方法
KR101916956B1 (ko) * 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
BR112019018022A2 (pt) * 2017-03-01 2020-06-02 Medimmune Limited Formulações de anticorpos monoclonais
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160130366A1 (en) * 2014-10-01 2016-05-12 Medimmune Limited Antibodies to ticagrelor and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BUCHANAN, A ET AL.: BLOOD, vol. 125, no. 22, 28 May 2015 (2015-05-28), pages 3484 - 3490, XP055236572, [retrieved on 20150318], DOI: 10.1182/blood-2015-01-622928 *
PEHRSSON S. ET AL: JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 15, no. 6, 11 May 2017, pages 1213 - 1222, Retrieved from the Internet DOI: 10.1111/jth.13680 *

Also Published As

Publication number Publication date
ES3042247T3 (en) 2025-11-19
US20210347915A1 (en) 2021-11-11
WO2020061465A1 (en) 2020-03-26
EP3852617A1 (en) 2021-07-28
KR20210091698A (ko) 2021-07-22
CA3113654A1 (en) 2020-03-26
JP2024096134A (ja) 2024-07-12
EP3852617B1 (en) 2025-09-10
KR20250161038A (ko) 2025-11-14
AU2019342755A1 (en) 2021-05-06
DK3852617T3 (da) 2025-10-20
EP4653465A2 (en) 2025-11-26
JP2022501368A (ja) 2022-01-06
JP7478975B2 (ja) 2024-05-08
MX2021003298A (es) 2021-08-11
KR102880762B1 (ko) 2025-11-03
EP4653465A3 (en) 2026-01-07
EP3852617A4 (en) 2022-08-24
FI3852617T3 (fi) 2025-10-21
CN113194821B (zh) 2025-07-04
PL3852617T3 (pl) 2026-01-26
CN113194821A (zh) 2021-07-30

Similar Documents

Publication Publication Date Title
AU2019342755B2 (en) Methods of reversing ticagrelor activity
CA2994447C (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
KR20190044673A (ko) 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법
EP3554543A2 (en) Stable aqueous anti-c5 antibody composition
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
JP2022501368A5 (https=)
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
US20230192895A1 (en) Pharmacokinetic & pharmacodynamic model for determining effective dose of anti-ticagrelor antibody
AU2017355613B2 (en) Treatment regimens
JP7842164B2 (ja) 治療用抗体製剤
US20200055942A1 (en) Treatment regimens
JPWO2020061465A5 (https=)
RU2794143C2 (ru) Способы лечения первоначального эпизода ttp с помощью одиночных вариабельных доменов иммуноглобулинов
HK40119109A (en) Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders
EA050545B1 (ru) Терапевтические составы антитела
WO2023107100A1 (en) Methods and treatment for multiple myeloma involving antibodies to il-18

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SFJ PHARMACEUTICALS X, LTD.

Free format text: FORMER APPLICANT(S): PHASEBIO PHARMACEUTICALS, INC.

HB Alteration of name in register

Owner name: SFJ PHARMA X, INC.

Free format text: FORMER NAME(S): SFJ PHARMACEUTICALS X, LTD.

FGA Letters patent sealed or granted (standard patent)